Global Automated Blood Culture Tests Market Size (2024-2030)

The Global Automated Blood Culture Tests Market reached a valuation of USD 4.63 Billion in 2024 and is poised to attain a market size of USD 9.16 Billion by 2030. The market is forecasted to achieve a Compound Annual Growth Rate (CAGR) of 10.23% during the projection period from 2024 to 2030.

Market Synopsis:

The Automated Blood Culture Test is a method used to detect the presence of microorganisms in the bloodstream, such as bacteria or fungi. It serves to identify the root cause of bloodstream infections and recommend appropriate treatment measures. Typically, alongside automated blood culture testing, two diagnostic tests—total blood count and chemical analysis—are conducted. Blood culture tests play a vital role in diagnosing numerous infectious diseases. The market is expected to witness growth, driven by the escalating prevalence of infectious ailments and advancements in diagnostic technologies. Moreover, the market is projected to benefit from factors such as an aging geriatric populace, the necessity for swift diagnosis and treatment, and the alarming global statistics reported by the World Health Organization, citing over 17.1 million deaths annually due to infectious diseases. Furthermore, increased research and development (R&D) investments and enhanced public awareness regarding early diagnosis are anticipated to bolster market expansion in the forecasted period. The automated blood culture tests market has been on an upward trajectory owing to the heightened demand for rapid diagnoses, notably prompted by the rising incidents of hospital-acquired infections, infectious diseases, and compromised immunity levels due to elevated pollution. However, stringent regulations and compliance standards in regions like North America and Europe pose as impediments to market growth.

COVID-19 Impact on the Automated Blood Culture Tests Market:

The onset of the COVID-19 outbreak in China in December 2019 swiftly escalated into a global pandemic. Countries such as China, Italy, Iran, Spain, South Korea, France, Germany, and the US bore the brunt of the outbreak in terms of confirmed cases and reported fatalities. The pandemic significantly disrupted various industries across nations due to widespread lockdowns and business closures. The healthcare sector, in particular, faced substantial challenges, including disruptions in the supply chain, technological events, and office closures. This crisis impeded market growth in several ways, including production and demand downturns, financial repercussions on the manufacturing industry, and supply chain interruptions. The prevalence of bloodstream infections and related diseases has notably surged in recent years. Additionally, lifestyle changes induced by lockdowns, such as reduced physical activity, irregular sleep patterns, unhealthy dietary habits, and stress, have contributed to disrupted bodily rhythms. The overall market downturn, exacerbated by the COVID-19 pandemic, was further compounded by factory closures, supply chain disruptions, and a global economic downturn.

Market Drivers:

The escalating incidence of bloodstream infections is propelling the demand for automated blood culture tests:

Bloodstream infections, including healthcare-associated infections, stand as leading causes of mortality worldwide. The US alone reports over 255,000 hospital-acquired bloodstream infection cases annually. Globally, approximately 33 million individuals suffer from bloodstream infections each year, with 3 million infants and 1.2 million children developing sepsis, and the remainder, 6.1 million, succumbing to fatal outcomes. In Eastern Africa, bloodstream infections are estimated to afflict between 11% to 28% of patients. According to the Journal of Tropical Medicine (2019), Ghana reports bloodstream infection rates ranging from 9.3% to 11.2%. These heightened infection rates prolong hospital stays and elevate overall treatment expenses, factors that are anticipated to drive the demand for automated blood culture tests, consequently expanding the market size in the forthcoming years.

Government initiatives and investments are fostering the market growth rate:

Increased government endeavors to promote research and development (R&D) and manufacturing of automated blood culture test products, along with rising healthcare awareness aimed at mitigating disease risks, are bolstering market expansion. Additionally, the implementation of regulatory frameworks pertaining to R&D associated with advanced diagnostic devices and technologies is poised to further stimulate market growth.

Growing investments in R&D and novel technologies within the Healthcare sector are fueling market growth:

Noteworthy private capital investments in pharmaceutical R&D, coupled with the approval and introduction of new therapies and technologies, have witnessed remarkable growth in recent years. Notably, between 2017 and 2020, spending on Research and Development surged by nearly 65%. This surge in competition and continuous innovations within the pharmaceutical industry is driving the automated blood culture tests market.

Market Restraints:

The high costs associated with automated instruments and technologies for blood culture tests are impeding market growth:

Automated blood culture test equipment entails substantial expenses due to its advanced features and functionalities. Additionally, maintenance costs and other indirect expenditures contribute to increased overall costs. Consequently, this poses a significant barrier for small-scale end-users in adopting automated blood culture tests.

Increased technological advancements in the market are decelerating the global market size growth:

Numerous companies are introducing cutting-edge technologies to compete with traditional equipment such as polystainers and microscopes. Key market players are investing in and adopting new technologies to diversify their product and service portfolios, thereby maintaining market competitiveness. This trend is anticipated to slow down the growth of the global automated blood culture tests market.

Automated Blood Culture Tests Market – Product.

• Consumables

• Bacterial Infections
• Fungal Infections
• Mycobacterial Infections
• Assay, Kits, and Reagents
• Blood Culture Accessories
• Blood Culture Media
• Aerobic
• Anaerobic
• Fungi/Yeast
• Others

• Instruments

• Bacterial Infections

• Fungal Infections
• Mycobacterial Infections
• Automated Blood Culture Systems
• Laboratory Equipment
• Incubators
• Colony counters
• Microscopes
• Gram stainers

• Software & Services

• Bacterial Infections

• Fungal Infections
• Mycobacterial Infections

The automated blood culture tests market is divided into three segments based on the product: Consumables, Instruments, and Software & Services.

Consumables represent the largest share of revenue as of 2022, driven primarily by a high rate of consumable purchases.

The Instruments segment is expected to demonstrate a notable Compound Annual Growth Rate (CAGR) throughout the forecast period. Automated systems, incubators, microscopes, and gram stainers are commonly used in hospitals, clinics, and diagnostic labs. Companies focused on diagnostic services and technologies are introducing advanced technologies to meet customer needs. Modern automated techniques provide highly accurate results quickly and efficiently, with minimal risk of contamination.

Automated Blood Culture Tests Market – Technology.

• Culture-based Technology
• Proteomic Technology
• Molecular Technology
• PCR
• Microarray
• PNA-FISH

The automated blood culture tests market is segmented into three technology categories: Culture-based Technology, Proteomic Technology, and Molecular Technology.

The technology segment commands the largest share of market revenue and leads the market.

Molecular Technology is expected to drive this segment and exhibit the highest CAGR from 2024 to 2028. There is a growing demand for rapid diagnostic methods to identify bacterial or fungal infections in the blood, fueled by increased research and development expenditures by manufacturers and the rising prevalence of infectious diseases. The market is projected to expand due to the increased demand for advanced diagnostic tools such as microarrays, PCR, and Peptide Nucleic Acid (PNA). The PNA-FISH technology sub-segment is anticipated to grow at the highest CAGR during the forecast period, owing to its advantages such as improved accuracy, shorter test times, and enhanced test efficiency.

Automated Blood Culture Tests Market – Application.

• Bacterial Infections
• Fungal Infections
• Mycobacterial Infections

The automated blood culture tests market is segmented into three application categories: Bacterial Infections, Fungal Infections, and Mycobacterial Infections.

The bacterial infections segment holds the largest market share in terms of revenue as of 2022, as bacterial infections are the most common cause of Bloodstream Infections (BSI) and other infections. This segment is also estimated to have the highest CAGR during the forecast period. Growth in this segment is expected to be driven by increasing healthcare awareness and improved healthcare infrastructure in developing countries such as South Africa, Tanzania, China, India, and Argentina. Governments in these economies are working to provide higher-quality medical facilities and diagnostic tools.

Automated Blood Culture Tests Market – End-Use.

• Hospital Laboratories
• Reference Laboratories
• Others

The automated blood culture tests market is divided into three end-use segments: Hospital Laboratories, Reference Laboratories, and Others.

Hospital Laboratories currently dominate the global market share due to the increasing incidence of infections acquired in hospitals (HAIs). According to the World Health Organization (WHO), developing countries have infection rates two to three times higher than industrialized nations. Furthermore, the hospital laboratory segment is expected to grow at the highest CAGR throughout the forecast period. The growth is being driven by increasing public awareness of healthcare issues, along with government and non-governmental organizations' initiatives to prevent and control infectious diseases.

The reference laboratories market sector is expected to experience profitable growth throughout the forecast period, attributed to an increase in hospitals outsourcing their blood culture testing. Reference laboratories are equipped with advanced diagnostic tools that deliver faster, more accurate, and efficient results.

Automated Blood Culture Tests Market – Region.

• North America
• Europe
• South America
• Asia-Pacific
• Middle-East and Africa

The automated blood culture tests market is segmented into five major regions: North America, Europe, South America, Asia-Pacific, and Middle-East and Africa.

North America leads the global market with the highest revenue share in 2022, owing to the presence of major healthcare organizations such as Becton, Dickinson and Company, bioMérieux SA, Thermo Fisher Scientific, Inc., and Roche Diagnostics.

Europe is expected to witness market growth due to the availability of advanced diagnostic technologies and highly developed healthcare infrastructure in countries like Germany, the U.K., Switzerland, and France. Additionally, increased research and development investments by manufacturers are expected to drive growth.

Asia Pacific is anticipated to have the highest CAGR during the forecast period, driven by a high prevalence of infectious diseases and the growth of healthcare infrastructure. Many businesses are focusing on Asian economies such as China and India for economic growth. Major drivers in the region include a large base of target consumers and rising disposable income.

Automated Blood Culture Tests Market – Companies.

1. Becton Dickenson and Company
2. Thermo Fisher Scientific
3. bioMérieux SA
4. Luminex Corporation
5. Danaher Corporation
6. Bruker Corporation
7. IRIDICA
8. Roche Diagnostics
9. T2 Biosystems
10. Anaerobe Systems
11. OpGen
12. Meditech Technologies India Private Limited
13. Carl Zeiss AG
14. Nikon Corporation
15. BINDER GmbH
16. Biobase Biotech
17. Scenker Biological Technology Co.
18. Bulldog Bio
19. Axiom Laboratories
20. HiMedia Laboratories

Key Recent Industry Developments:

In May 2022, Biomérieux SA, a key leader in in-vitro diagnostics, acquired Specific Diagnostics.